309 related articles for article (PubMed ID: 30151723)
1. Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.
Serajeddini H; Rogliani P; Mura M
Lung; 2018 Dec; 196(6):707-713. PubMed ID: 30151723
[TBL] [Abstract][Full Text] [Related]
2. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.
Khadawardi H; Mura M
Respirology; 2017 Apr; 22(3):501-507. PubMed ID: 27862639
[TBL] [Abstract][Full Text] [Related]
3. Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis.
Nyilas S; Schreder T; Singer F; Poellinger A; Geiser TK; Latzin P; Funke M
Respirology; 2018 Aug; 23(8):764-770. PubMed ID: 29573509
[TBL] [Abstract][Full Text] [Related]
4. Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment.
Fisher JH; Al-Hejaili F; Kandel S; Hirji A; Shapera S; Mura M
Respir Med; 2017 Apr; 125():65-71. PubMed ID: 28340864
[TBL] [Abstract][Full Text] [Related]
5. Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis.
Bahmer T; Kirsten AM; Waschki B; Rabe KF; Magnussen H; Kirsten D; Gramm M; Hummler S; Brunnemer E; Kreuter M; Watz H
Respiration; 2016; 91(6):497-502. PubMed ID: 27240427
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.
Bahmer T; Kirsten AM; Waschki B; Rabe KF; Magnussen H; Kirsten D; Gramm M; Hummler S; Brunnemer E; Kreuter M; Watz H
BMC Pulm Med; 2017 Jul; 17(1):104. PubMed ID: 28743305
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
Hosein K; Le J; Mura M
Lung; 2017 Feb; 195(1):101-105. PubMed ID: 27858160
[TBL] [Abstract][Full Text] [Related]
9. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.
Tzouvelekis A; Herazo-Maya JD; Slade M; Chu JH; Deiuliis G; Ryu C; Li Q; Sakamoto K; Ibarra G; Pan H; Gulati M; Antin-Ozerkis D; Herzog EL; Kaminski N
Respirology; 2017 Apr; 22(3):486-493. PubMed ID: 27761978
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Role of Ventilatory Inefficiency and Exercise Capacity in Idiopathic Pulmonary Fibrosis.
Vainshelboim B; Oliveira J; Fox BD; Kramer MR
Respir Care; 2016 Aug; 61(8):1100-9. PubMed ID: 27165419
[TBL] [Abstract][Full Text] [Related]
11. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
12. Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases.
Zanini U; Luppi F; Kaur K; Anzani N; Franco G; Ferrara G; Kalluri M; Mura M
Respirology; 2024 May; 29(5):387-395. PubMed ID: 38320863
[TBL] [Abstract][Full Text] [Related]
13. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
[TBL] [Abstract][Full Text] [Related]
14. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
Garin MC; Highland KB; Silver RM; Strange C
J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.
Kimura M; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Nishiyama O; Aso H; Sakamoto K; Hasegawa Y
Respiration; 2013; 85(6):456-63. PubMed ID: 23257350
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.
Ley B; Bradford WZ; Vittinghoff E; Weycker D; du Bois RM; Collard HR
Am J Respir Crit Care Med; 2016 Sep; 194(6):711-8. PubMed ID: 26938706
[TBL] [Abstract][Full Text] [Related]
17. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.
Swigris JJ; Han M; Vij R; Noth I; Eisenstein EL; Anstrom KJ; Brown KK; Fairclough D
Respir Med; 2012 Oct; 106(10):1447-55. PubMed ID: 22801586
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
[TBL] [Abstract][Full Text] [Related]
19. Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.
Toi Y; Takei R; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Fukuoka J; Johkoh T; Kondoh Y
Respir Investig; 2021 May; 59(3):335-341. PubMed ID: 33551330
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study.
Tonelli R; Cocconcelli E; Lanini B; Romagnoli I; Florini F; Castaniere I; Andrisani D; Cerri S; Luppi F; Fantini R; Marchioni A; Beghè B; Gigliotti F; Clini EM
BMC Pulm Med; 2017 Oct; 17(1):130. PubMed ID: 29017478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
